Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin

Endocrine Journal

Mitsuyoshi Takahara¹  Toshihiko Shiraiwa²  Naoto Katakami¹  Iichiro Shimomura¹  Taka-aki Matsuoka¹ 

[1] Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan;Shiraiwa Medical Clinic, Osaka, Japan

关键词: Sodium-glucose cotransporter 2 (SGLT2) inhibitor;    Ipragliflozin;    β cell function;    Disposition index;    Washout;   

DOI  :  10.1507/endocrj.EJ14-0335

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(35)Cited-By(6)It remains to be seen whether pancreatic β cell dysfunction in type 2 diabetic patients can be ameliorated just by correcting hyperglycemia.The current pilot study investigated β cell function after a four-week treatment with a sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus.Ten participants (age, 51 ± 13 years; hemoglobin A1c levels, 9.4 ± 1.0%) took 50 mg of ipragliflozin L-proline for four weeks and thereafter discontinued the agent for one week.A 75-g oral glucose tolerance test (OGTT) was performed at 0 (baseline), 4 (end of medication), and 5 weeks (end of washout).The β cell function was evaluated using the disposition index, which was calculated as the product of the ΔIns0-120/ΔGlu0-120 and the Matsuda index, where ΔIns0-120/ΔGlu0-120 represents the ratio of the incremental concentrations of insulin to those of glucose during the 0- to 120-min time period of the OGTT.The fasting glucose level was 182 ± 34 mg/dL at 0 week, 137 ± 20 mg/dL at 4 weeks (p < 0.001), and 154 ± 31 mg/dL at 5 weeks (p = 0.001).Compared to baseline, the disposition index was significantly elevated not only at 4 weeks (p < 0.001) but also at 5 weeks (p = 0.008).In conclusion, the current pilot study showed that the β cell function assessed by the OGTT-derived disposition index was significantly improved after a four-week treatment with ipragliflozin in Japanese patients with type 2 diabetes mellitus.

【 授权许可】

Unknown